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ABSTRACT 
Objectives: The direct method is a procedure designed to cause less pain during insertion of 
an intrauterine contraceptive device (IUCD). It was first reported in 2005 and differs from the 
standard method of insertion recommended by IUCD manufacturers. In France, the direct 
method is well known and used by experienced practitioners, but it has never been evaluated 
against the standard method of insertion. The aim of the study was therefore to compare the 
direct method with the standard method in terms of pain experienced during insertion and the 
side effects and satisfaction rates over 6 months. 
Methods: A prospective observational study was conducted in France between June and 
December 2016 to compare the direct and standard methods of IUCD insertion. 
Results: The study included 535 women: 281 in the direct method group (DM group) and 254 
in the standard method group (SM group). Women in the DM group reported less pain. This 
difference was assessed by multilevel multivariate analysis (−8.3 mm, 95% confidence 
interval [CI] −14.3, −2.3). There was no difference in the occurrence of infection (1.4% vs 
2.8%; p=0.366) and 6 month continuation rates (89.4% vs 89.2%; p=0.936). Satisfaction rates 
at 6 months were higher in the DM group (93.6% vs 87.4%; p=0.019). 
Conclusion: The results of the study suggest that the direct method of IUCD insertion is 
associated with less pain and does not increase the risk of adverse effects. Widespread 
adoption of the direct method could improve women’s comfort and lead to a higher uptake of 
the IUCD as a form of contraception. 
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Introduction 
Intrauterine contraceptive devices (IUCDs), including the copper-bearing intrauterine device (IUD) 
and the levonorgestrel-releasing intrauterine system (LNG-IUS), are highly effective methods of 
contraception and are associated with low complication rates [1-3]. Concerns about insertion pain 
may, however, be a potential barrier to their use as first-line contraception [4,5]. A study on IUD 
insertion showed that >50% of women experienced pain on insertion, with 11% scoring ≥50 mm on 
a 100 mm visual analogue scale (VAS) [6]. Reported mean VAS values vary between 40 and 60 
mm, with greater pain experienced by nulliparous women [6-11]. 
International recommendations suggest prescribing painkillers before the procedure but do not 
specify the molecule or the dosage [2,3,12]. Previous studies show contradictory findings for 
naproxen, tramadol and lidocaine in pain reduction during IUCD insertion, and misoprostol and 
other non-steroidal anti-inflammatory drugs (NSAIDs) have been found to be ineffective [13-15]. 
Pain management thus remains an area of improvement for women undergoing IUCD insertion. 
An experimental insertion method aimed at causing less pain was described in France in 2005 [16]. 
The method is called the ‘torpedo method’, ‘plunging insertion’ or the ‘direct method’ and can be 
used with T-shaped IUCDs (including the LNG-IUS). In the direct method, the inserter is 
introduced up to the internal cervical os (marked by resistance or an insertion depth of 3-4 cm), 
without passing through it, and the device is then propelled into the uterine cavity. This contrasts 
with the standard method, where the inserter is placed up to the uterine fundus. The purpose of the 
direct method technique is to facilitate insertion and avoid the pain caused by the inserter (which is 
wider than the IUCD) passing through the endocervical canal and reaching the uterine fundus. In 
2015, 15 health care professionals (HCPs) using the direct method reported improved patient 
comfort, improved success rates and similar ultrasound placement [17]. There is, however, a lack of 
quantitative data comparing the direct method with the standard method in terms of insertion pain 
and the ensuing tolerability and contraceptive effectiveness of the device. 
The aim of this study was to compare the pain experienced during IUCD placement with both 
procedures (direct and standard methods) and to observe adverse effects and user satisfaction over 6 
months. 
Methods 
Study design and population 
This prospective open-label cohort study was conducted in France. General practitioners (GPs), 
gynaecologists and midwives using exclusively either the direct or the standard method were 
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invited to participate. All HCP participants completed an online questionnaire about their IUCD 
insertion procedure practices and habits. The following data were collected: university and 
continuous education; number of years’ experience of IUCD insertion; number of IUCD insertions 
performed per year; use of premedication or of a drug-free strategy such as inviting the woman to 
introduce the vaginal speculum herself or of using the lateral decubitus position (right or left lateral 
decubitus may improve the woman’s comfort during a gynaecological examination [18]); and the 
use of a tenaculum or hysterometer. HCPs carrying out fewer than 10 IUCD insertions per year 
were excluded from the study. 
All women consulting one of the participating HCPs for IUCD insertion between 15 June and 15 
December 2016 were invited to participate. Women recruited by direct method users were included 
in the direct method group (DM group) and those recruited by standard method users were included 
in the standard method group (SM group). The only exclusion criterion was the use of a non-T-
shaped IUCD. 
The primary outcome was the pain experienced during IUCD insertion. Secondary outcomes were 
procedure failure rate, occurrence of immediate side effects, satisfaction with the procedure, and 
tolerability and effectiveness at 1 and 6 months. 
Women received written information on the day of enrolment, explaining the two different insertion 
techniques and the possibility of a higher risk of IUCD failure or expulsion with the direct method, 
the purpose of the study, the data processing method and the possibility of recovering their own data 
at any point. Entering the study had no influence on the care given, especially on the choice of 
insertion technique (the study was only observational). The protocol was submitted to the 
institutional review board of Rennes University Hospital for approval (no. 16.55, 21/04/2016) and 
registered with the Commission Nationale de l’Informatique et des Libertés (no. 1935248v1, 
13/04/2016), according to French law. 
Neither the women nor the HCPs received any financial reward. 
Data collection 
All questionnaires were standardised and validated by the Department of Epidemiology and Public 
Health of Rennes University Hospital. Participating women completed two self-administered 
questionnaires alone on the day of enrolment. The first was filled in immediately before the 
procedure (i.e. in the waiting room) and comprised demographic characteristics, gynaecological and 
obstetric history, feelings of anxiety, and anticipated pain. The women were not asked about the 
phase of their menstrual cycle at the time of IUCD insertion, as this factor has been shown not to 
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influence insertion pain [19]. The second questionnaire was filled in by the woman on returning to 
the waiting room immediately after the consultation and comprised questions about premedication 
(whether prescribed by the HCP or self-medication), consultation atmosphere (very soothing, quite 
soothing, stressful or very stressful), pain experienced during and after IUCD insertion (expressed 
using a standardised 100 mm VAS: 0=no pain, 100=worst imaginable pain), adverse events, success 
of the procedure and satisfaction with the procedure. The two questionnaires were sent to the 
principal investigator (AB) in a stamped addressed envelope, ensuring data confidentiality. 
Participating women were called or emailed up to five times by the principal investigator, 1 month 
and 6 months after the procedure, and the following data were collected: pain experienced and 
occurrence of side effects requiring medical advice during the month following insertion, 6 month 
continuation or motive for discontinuation, 6 month complications, and satisfaction with the IUCD. 
Statistical analysis 
Univariate analysis was performed using χ2 and Fisher’s exact tests for qualitative variables and 
Student’s t test for quantitative variables. Multilevel multivariate analysis using a random intercepts 
model was performed to control for correlation induced by recruitment design. The criterion 
‘insertion pain’ was analysed as a continuous variable using multivariate linear regression analysis. 
Observations with missing data were excluded from the analysis. 
Results 
Population 
Of the 200 HCPs who were invited to participate, 61 completed the online survey. Four were 
excluded since they carried out fewer than 10 insertions per year, and a further six failed to recruit 
any women within the 6 month study period. The final number of participants was 51: 26 GPs, 12 
gynaecologists and 13 midwives. Of these, 25 were recruited for the DM group and 26 for the SM 
group. The two recruiting groups were similar in size, sex ratio (p=0.191), age (p=0.313), education 
(years of experience; p=0.066) and number of procedures carried out per year (p=0.657). 
According to the estimated activity of the participating HCPs, approximately 1500 women 
underwent IUCD insertion between 15 June and 15 December 2016. All women were invited to 
participate. Overall, 541 women who returned completed questionnaires were recruited. Six women 
did not meet the inclusion criteria, leaving 281 in the DM group and 254 in the SM group (Figure 
1). HCPs from the DM group recruited between one and 36 women (mean 10.04, standard deviation 
[SD] 8.6) and HCPs from the SM group recruited between one and 29 women (mean 8.47, SD 8.1). 
Ac
ce
pte
d 
an
us
cri
pt
The groups were similar with regard to baseline characteristics (Table 1). Mean previous pregnancy 
rates were 1.24 (SD 1.1) in the DM group and 1.26 (SD 1.1) in the SM group (p=0.815). 
The IUCD insertion procedures are detailed in Table 1. Anticipated pain was higher in the SM 
group (p=0.031). The use of premedication was more frequent in this group (p<0.001) and was 
associated with anticipated pain in the study population as a whole (p<0.001) and in the SM group 
(p=0.029). The use of a drug-free strategy was more frequent in the DM group (p<0.001). Some 
women received more than one premedication, more than one drug-free strategy, or even a 
combination of premedication and drug-free strategy. The use of a tenaculum and hysterometer was 
more frequent in the SM group (p<0.001). 
Insertion pain: univariate and multivariate analyses 
Univariate analysis of VAS values showed less insertion pain in the DM group (median 13 mm, 
mean 19.9 mm, SD 22.5) compared with the SM group (median 24 mm, mean 33.4 mm, SD 29.3) 
(p<0.001) (Table 2, Figure 2). This was also true for the nulliparous women in the DM group 
(median 23 mm, mean 28.5 mm, SD 24.7) vs the SM group (median 53.5 mm, mean 51.3 mm, SD 
27.3) (p<0.001) (Figure 2). Age, parity, vaginal or caesarean delivery in the preceding 3 months, 
current breastfeeding, first experience of IUCD insertion, profession of the HCP and consultation 
atmosphere were also significantly associated with insertion pain (Table 2). 
Multivariate analysis of insertion pain predictors indicated that use of the direct method was 
independently associated with less insertion pain by a VAS value of 8.3 mm (95% confidence 
interval [CI] −14.3, −2.3). The number of previous vaginal deliveries, a vaginal or caesarean 
delivery in the preceding 3 months and a ‘very soothing’ consultation atmosphere were also 
independently associated with less pain. A history of IUCD insertion failure, high anticipation of 
pain, and the use of a tenaculum were independently associated with greater pain (Table 3). 
IUCD insertion: secondary outcomes 
Secondary outcomes are detailed in Table 4. Vasovagal symptoms occurred more frequently in the 
SM group (p=0.036). One woman in this group reported syncope (p=1.0). In multivariate analysis 
the occurrence of vasovagal symptoms was correlated with the level of pain during insertion (odds 
ratio [OR] 1.03 [95% CI 1.01, 1.04] per 10 mm VAS value increase). Other side effects were mild 
and rare. 
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Nine insertion attempts failed: three (1.1%) in the DM group and six (2.4%) in the SM group 
(p=0.322). 
In the DM group, 87% of women were ‘very satisfied’ with the procedure vs 84% of women in the 
SM group (p=0.729). Multivariate analysis identified the ‘very soothing’ atmosphere of the 
consultation (OR 1.20 [95% CI 1.13, 1.28]) and the low level of insertion pain (OR 1.04 [95% CI 
1.03, 1.05] per 10 mm VAS value decrease) as significant predictors of a high level of satisfaction. 
Follow-up at 1 month 
Response rates were good at 1 and 6 months. Pain during the first month was lower in the DM 
group than in the SM group (p<0.001). The occurrence of adverse effects requiring medical advice 
was higher in the SM group (19% vs 10% in the DM group; p=0.003). Pain was the most common 
reason and was more frequent in the SM group (p<0.001). There were no differences in the 
occurrence of other side effects: bleeding, device expulsion, mycosis, pelvic infection, nausea, 
hormonal symptoms and request for device removal (Table 4). 
Follow-up at 6 months 
The 6 month IUCD continuation rate was 89.4% in the DM group and 89.2% in the SM group 
(p=0.936). One unintended pregnancy occurred in the DM group (due to a partially expelled device) 
vs none in the SM group (p=1.0). The woman chose to terminate the pregnancy. There were four 
cases (1.4%) of pelvic infection requiring antibiotics in the DM group and seven cases (2.8%) in the 
SM group (p=0.366). No uterine perforation or device migration was reported (Table 4). The 6 
month IUCD satisfaction rate was 93.6% in the DM group vs 87.4% in the SM group (p=0.019). 
Discussion 
Findings and interpretation 
This observational study shows significantly less insertion pain with the direct method of IUCD 
insertion compared with the standard method, as well as fewer side and adverse effects up to 6 
months following device insertion. Various explanatory factors may be assumed. The insertion 
technique itself may cause less pain, since the IUCD passes through the internal cervical os without 
the inserter (which is of greater diameter), and the physical contact of the fundus by the IUCD at 
placement is less severe with the direct method compared with the standard method. In addition, the 
direct method is a way of simplifying the insertion procedure with a shorter procedure duration and 
fewer intrauterine manipulations, thereby causing less pain [20]. Finally, with the direct method 
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there is no need to use a hysterometer and, in most cases, a tenaculum, which have been described 
as the most painful stages of the procedure [21,22]. 
Use of the direct method may thus reduce the need for preventive analgesics: painkillers and other 
premedication were prescribed less often by HCPs using the direct method. These included 
potentially poorly tolerated drugs such as misoprostol and tramadol. 
There was no increase in the incidence of either mild or severe adverse events with the direct 
method. The sample size was, however, too small to draw any conclusions about the safety of the 
technique. 
Strengths and weaknesses of the study 
The main strength of the study lies in the novelty of evaluating the direct method of IUCD insertion 
in a prospective comparative study of a large sample of women (>500). The characteristics of our 
population, recruited throughout France, were similar to those found in IUCD users described in the 
literature [23,24]: age 17–54 years, about 55% over the age of 30, one-third nulliparous, about 56% 
first-time IUCD users. We can thus assume that the study sample was representative of the target 
population. The DM and SM groups were similar and the follow-up rate was high. 
Some limitations should, however, be mentioned. We decided to include HCPs who exclusively 
used only one of the two methods, to avoid overestimation of direct method pain: HCPs using both 
methods usually choose the direct method when anticipating a difficult insertion. This choice, 
however, somewhat limits the comparability of the direct and standard methods: HCPs using the 
direct method may be more fully committed to pain reduction, thus introducing a possible bias. 
There were significant differences between groups in the use of pain control strategies, which might 
also have presented bias. The use of pain medications was less frequent in the DM group, which 
had lower pain scores, so the bias was in the opposite direction. The DM group more often used 
drug-free strategies, which may be a confounder; nevertheless, the efficacy of such strategies has 
never been demonstrated. 
Moreover, the study was observational and non-randomised for ethical reasons, since there is no 
current evidence in the literature recommending the use of the direct method, and the recruitment 
was based on voluntary participation. 
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Similarities and differences in relation to other studies 
To our knowledge, no quantitative study of the direct method has been published to date. With the 
standard method, the reported VAS values for IUCD insertion pain vary considerably (18–60 mm) 
[6-11]. Predictors of pain identified in our study were similar to those found by others. Nulliparity 
and absence of vaginal deliveries are associated with greater pain [6-11,25], and less pain is 
experienced during the early postpartum period [6,8,9]. Anxiety and anticipated pain are associated 
with greater pain [6,8,25]. We found no data, however, about the influence of previous IUCD 
insertion failure. After controlling for a recent (<3 months) obstetric event, breastfeeding did not 
significantly improve the model. Unlike larger studies, we found no association between 
breastfeeding and lower pain [6,26], possibly owing to a lack of statistical power. 
Open questions and future research 
One unintended pregnancy occurred in the DM group due to a partially expelled device. This 
observation should encourage further studies to assess the contraceptive efficacy of IUCDs inserted 
with the direct method. It is known that low-lying and malpositioned copper-bearing IUDs are 
associated with a higher risk of pregnancy [27,28] and device expulsion [29,30] (while the efficacy 
of a low-lying LNG-IUS does not seem to be reduced [31]), but no threshold value has been defined 
to predict the risk. Systematic sonography is not recommended after a standard method IUCD 
insertion [1-3], but some authors consider that contraceptive efficacy cannot be guaranteed if the 
device is positioned >2 cm from the fundus [3]. IUCDs often move, however, during the 3 months 
following insertion [32]. 
Most women in both groups were ‘very satisfied’ with the insertion procedure, including those 
having experienced a high level of pain or insertion failure. Although this may be interpreted as a 
marker of the quality of the consultation (good listening techniques, clear and comprehensible 
information, consideration of anxiety and pain), it also raises questions about the societal and 
cultural aspects of gynaecological care: women may feel that gynaecological or procreation-induced 
pain is inevitable and therefore may subsequently feel disinclined to complain. 
Conclusion 
Although larger tolerability studies are required, the direct method seems to be a safe and less 
painful procedure for IUCD insertion than the standard method, with a high continuation rate at 6 
months and similar high efficacy. These new results thus strongly support the use of the direct 
method, pending confirmation by a randomised controlled trial. 
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Table 1. Demographic characteristics of the study population and circumstances of device 
insertion. 
Variable DM group (n=281)  SM group (n=254) p-value 
 n %  n %  
Participants’ questionnaire       
 Age, in years, mean±SD (range) 32.03±7.7 
(17–52) 
  31.80±7.4 
(17–54) 
 0.718 
 No. of previous pregnancies       
  0 93 33.1  87  34.3 0.766 
  1–2 160 56.9  137  53.9  
  3–6 28 10.0  29  11.4  
 No. of previous vaginal deliveries       
  0 121  43.0  104  40.9 0.839 
  1–2 134  47.7  128  50.4  
  3–6 24  8.5  21 8.3  
 No. of previous caesarean deliveries       
  0 234  83.3  220  86.6 0.279 
  1–2 43 15.3  29 11.4  
  3–4 2 0.7  4 1.6  
 Gynaecological or obstetric event in the 
preceding 3 months 
      
  Vaginal delivery 44 15.7  32 12.6 0.311 
  Caesarean delivery 9 3.2  3 1.2 0.148 
  Abortion 22 7.8  11 4.3 0.093 
 Breastfeeding 35 12.5  29 11.4 0.712 
 Dysmenorrhoea 80 28.5  72 28.3 1.0 
 History of sexually transmitted infection 31 11.0  24 9.4 0.564 
 Type of HCP       
  GP 122 43.4  91 35.8 0.093 
  Gynaecologist 106 37.7  119 46.9  
  Midwife 53 18.9  44 17.3  
 Type of IUCD       
  Copper-bearing IUD 171 60.9  164 64.6 0.501 
  LNG-IUS 98 34.9  83 32.7  
 First IUCD insertion procedure 160 56.9  140 55.1 0.675 
 Previous IUCD insertion failure 5 1.8  7 2.8 0.446 
 Preliminary anxiety (VAS score) 29.32±26   31.61±26.5  0.316 
 Anticipated pain (VAS score) 37.41±24.8   42.22±26.3  0.031 
 Premedication 156 55.5  195 76.8 <0.001 
  NSAIDs 58 20.6  83 32.7 0.016 
  Tramadol or nefopam 1 0.4  14 5.5 <0.001 
  Paracetamol 13 4.6  9 3.5 0.529 
  Phloroglucinol 97 34.5  108 42.5 0.056 
  Misoprostol 0 0  25 9.8 <0.001 
  Benzodiazepine 2 0.7  8 3.1 0.055 
  Homeopathy or phytotherapy 8 2.8  26 10.2 0.001 
  Combination of several drugs 19 6.8  59 23.2 <0.001 
 Consultation atmosphere       
  Very soothing 197 70.1  195 76.8 0.021 
  Quite soothing 82 29.2  53 20.9  
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  Stressful 0 0  3 1.2  
  Very stressful 0 0  0 0  
HCP questionnaire       
 Drug-free strategy 176 62.6  57 22.4 <0.001 
  Patient insertion of speculum 62 22.1  57 22.4 0.933 
  Lateral decubitus 91 32.4  7 2.8 <0.001 
  Hypnosis and sophrology 42 14.9  29 11.4 0.293 
  Full bladder 10 3.6  7 2.8 0.608 
 Use of tenaculum       
  Systematic 0 0  50 19.7 <0.001 
  Only if insertion attempt fails 229 81.5  204 80.3  
  Never 52 18.5  0 0  
 Use of hysterometer       
  To measure uterine depth 0 0  141 55.5 <0.001 
  To determine cervical axis 119 42.3  61 24.0  
  Never 162 57.7  52 20.5  
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Table 2. Level of pain at insertion, by insertion method and women’s characteristics. 
Background characteristic VAS score (mean±SD) p-value 
Method of IUCD insertion   
 Direct method 19.86±22.5 <0.001 
 Standard method 33.35±29.3  
Age, years   
 17–25 35.28±29.0 <0.001 
  >25 23.66±25.7 
Parity   
 Nulliparous 39.43±28.3 <0.001 
  Parous 19.60±23.4 
Vaginal deliveries    
 0 39.94±28.4  <0.001 
 1–6 18.43±22.5  
Caesarean deliveries   
 0 26.41±26.7 0.655 
 1–4 24.91±27.1  
Gynaecological or obstetric event in the 
preceding 3 months  
  
 None 29.59±27.5  
 Vaginal delivery 8.95±13.4 <0.001 
 Caesarean delivery 10.25±13.7 <0.001 
 Abortion 30.91±28.0 0.797 
Currently breastfeeding    
 Yes 14.94±20.8 <0.001 
 No 27.78±27.2  
Dysmenorrhoea   
 Yes 28.94±27.7 0.145 
 No 25.05±26.2  
History of sexually transmitted infection   
 Yes 25.75±25.9 0.920 
 No 26.12±26.7  
Type of IUCD   
 Copper-bearing IUD  26.40±26.4 0.843 
 LNG-IUS 25.90±27.5  
First IUCD insertion procedure   
 Yes 28.62±28.1 0.006 
 No 22.13±24.4  
Previous IUCD insertion failure   
 Yes 40.33±28.4 0.107 
 No 25.87±26.7  
Type of HCP   
 GP 31.07±27.9 0.060 
 Gynaecologist 24.16±26.2  
 Midwife 20.27±23.8  
Consultation atmosphere   
 Very soothing 24.30±25.9 0.010 
 Quite soothing 31.55±28.4  
 Stressful 32.50±33.2  
Premedication   
 No 21.18±29.3  
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 Yesa 28.65±27.7 0.003 
 Ibuprofena 31.82±30.0 0.002 
 Tramadola 49.13±35.1 0.059 
 Misoprostola 33.32±28.9 0.054 
aCompared with no premedication.  
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Table 3. IUCD insertion pain: two-level multivariate linear regression (95% CI) (479 
observations). 
Background characteristic Variation in VAS score 
(95% CI) 
Insertion technique (ref. standard method)  
 Direct method −8.3 (−14.3, −2.3) 
Age (per 10 years) −0.1 (−0.5, 0.2) 
No. of previous pregnancies (per occurrence) −0.2 (−4.2, 4.0) 
No. of previous vaginal deliveries (per occurrence) −4.2 (−8.3, −0.3) 
Gynaecological or obstetric event in the preceding 3 months  
 Vaginal delivery −12.4 (−18.5, −6.0) 
 Caesarean delivery −20.9 (−34.4, −7.3) 
 Voluntary interruption of pregnancy −1.2 (−9.6, 7.2) 
History of IUCD insertion (ref. previous successful insertion)  
 First insertion 2.6 (−2.1, 7.2) 
 Previous insertion failure  16.4 (2.2, 30.3) 
Initial anxiety (per 10/100 VAS score increase) 0.2 (−0.9, 1.4) 
Anticipated pain (per 10/100 VAS score increase) 2.0 (0.8, 3.2) 
Premedication (ref. no nefopam)  
 Nefopam 14.9 (−4.7, 35.3) 
Consultation atmosphere (ref. quite soothing, stressful or very stressful)  
 Very soothing  −7.3 (−12.2, −2.7) 
Use of tenaculum (ref. never)  
 Systematic 16.0 (2.7, 29.2) 
 Only if insertion attempt fails 10.7 (1.6, 19.8) 
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Table 4. Secondary outcomes. 
 DM group 
(n=281) 
 SM group 
(n=254) 
p-value 
 n %  n %  
Day of device insertion       
 Vasovagal symptoms 42 14.9  60 23.6 0.036 
 Cramps 11 3.9  4 1.6 0.124 
 Urinary symptoms 0 0  1 0.4 0.476 
 Insertion failure 3 1.1  6 2.4 0.322 
Pain during first week      0.338 
 No pain 110 39.1  83 32.7 – 
 Mild pain 59 21.0  65 25.6 – 
 Moderate pain  61 21.7  55 21.7 – 
 Severe pain  31 11.0  34 13.4 – 
Pain during first month      <0.001 
 No pain 205 73.0  163 64.2 – 
 Mild pain 30 10.7  21 8.3 – 
 Moderate pain  19 6.8  24 9.4 – 
 Severe pain  6 2.1  26 10.2 – 
1 month follow-up       
 Pain 5 1.8  24 9.4 <0.001 
 Bleeding 11 3.9  19 7.5 0.094 
 Device expulsion 1 0.4  2 0.8 0.608 
 Device removal 3 1.1  6 2.4 0.323 
 Mycosis 1 0.4  2 0.8 0.608 
 Infection 0 0  2 0.8 0.228 
 Vasovagal symptoms 1 0.4  4 1.6 0.199 
 Hormonal symptoms 0 0  2 0.8 0.228 
6 month follow-up       
 Device expulsion 4 1.4  2 0.8 0.689 
 Device removal 24 8.5  23 9.1 0.678 
 Pregnancy 1 0.4  0 0 1.0 
 Infection 4 1.4  7 2.8 0.366 
 Perforation 0 0  0 0 1.0 
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Figure 1. Flow chart. 
 
Figure 2. Pain scores in women undergoing IUCD insertion by the direct method or the standard 
method. 
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25	HCPs
using	the	direct	method
26	HCPs
using	the	standard	method
541	women
completed	the
questionnaires
535	women	included
281	in	the	DM	group 254	in	the	SM	group
6	excluded
2	non-T-shaped	IUCDs,	1
absence	of	insertion
attempt,	2	other	HCPs,	1
unknown	HCP	
278	IUCD	insertions
277	responded	to	main
outcome
248	IUCD	insertions
246	responded	to	main
outcome
3	insertion	failures 6	insertion	failures
261	women
responded	at
1	month
237	women
responded	at
1	month
17	lost	to	follow-up 11	lost	to	follow-up
265	women
responded	at
6	months
241	women
responded	at
6	months
13	lost	to	follow-up 7	lost	to	follow-up
About	1500	women
underwent	IUCD	insertion
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All	women	(n=526) No	vaginal	delivery	(n=218) Nulliparous	(n=174)
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